尽管弥漫性大 B 细胞淋巴瘤 (DLBCL) 的管理和治疗不断进步，但约 35% 的患者会出现复发或对一线化疗耐药。对于这些患者来说，结果远未令人满意，并且确实存在未满足的需求，即改善一线治疗并为复发/难治性疾病创造更好的选择。 Polatuzumab vedotin 是一种与单甲基 auristatin E (MMAE) 微管抑制剂缀合的抗 CD79b 抗体。该分子最近因在 III 期 POLARIX 研究中与利妥昔单抗、环磷酰胺阿霉素和泼尼松 (R-CHP) 一线组合取得的有希望的结果而受到关注，表明与标准 R-CHOP 相比，无进展生存期有所改善。通过将 polatuzumab 与利妥昔单抗和苯达莫司汀 (pola-BR) 联合使用，与复发/难治性患者的标准 BR 相比，polatuzumab vedotin 的完全缓解率和总生存期也取得了显着改善。根据这些研究的结果，多个国家的卫生当局批准了 polatuzumab vedotin 用于既往未经治疗的患者和复发/难治性 DLBCL 患者。在这篇综述中，我们总结了最近使用 polatuzumab vedotin 得出的主要研究的数据，并概述了正在进行的一线和复发/难治性 DLBCL 联合试验，概述了报告的毒性。

Despite continuous improvements in the management and treatment of diffuse large B cell lymphoma (DLBCL), approximately 35% of the patients experience relapse or are refractory to frontline chemotherapy. For these patients, outcomes are far from satisfactory, and a real unmet need exists to both improve frontline treatment and create better options for relapsed/refractory disease. Polatuzumab vedotin is an anti-CD79b antibody conjugated to the monomethyl auristatin E (MMAE) microtubule inhibitor. The molecule has recently been under the spotlights for the promising results of the frontline combination with rituximab cyclophosphamide doxorubicin and prednisone (R-CHP) in the phase III POLARIX study, demonstrating improved progression-free survival over standard R-CHOP. A remarkable improvement in terms of complete response rate and overall survival with polatuzumab vedotin has also been achieved by combining polatuzumab with rituximab and bendamustine (pola-BR) over the standard BR for relapsed/refractory patients. Based on the results of these studies, health authorities in several countries granted approval for polatuzumab vedotin both for patients with previously untreated and for relapsed/refractory DLBCL. In this review, we summarize the data of major studies recently concluded with polatuzumab vedotin, and we provide an overview of the ongoing combination trials for frontline and relapsed/refractory DLBCL, outlining reported toxicities.